WASHINGTON — The Food and Drug Administration on Thursday granted full approval to Paxlovid for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, making the Pfizer antiviral the first oral COVID-19 treatment to move from emergency authorization to a conventional FDA approval. The decision formalizes a therapy that has become a central outpatient tool for preventing hospitalization and death in vulnerable adults while preserving emergency-authorized access for eligible adolescents.

The FDA’s May 25 announcement said the agency approved co-packaged nirmatrelvir and ritonavir after reviewing clinical-trial and post-authorization evidence. Paxlovid remains indicated for patients who have tested positive, have mild-to-moderate illness and face a high risk of severe outcomes. It is not approved for prevention before or after exposure and is not a substitute for vaccination.

Approval rests on a large reduction in severe outcomes

The pivotal evidence came from the EPIC-HR trial, published in the New England Journal of Medicine. In high-risk, unvaccinated, nonhospitalized adults treated early in illness, nirmatrelvir-ritonavir reduced the relative risk of COVID-19 hospitalization or death by about 88% compared with placebo in the final analysis. No deaths occurred in the treatment group through day 28, compared with 13 in the placebo group.

Pfizer’s approval statement described an 86% reduction in the risk of COVID-19-related hospitalization or death when treatment began within five days of symptom onset under the analysis submitted for the application. The practical message is consistent across analyses: the drug’s benefit is concentrated in people at meaningful risk of progression and depends on starting treatment early, generally within five days of symptoms.

FDA reviewed the evidence beyond the emergency phase

The approval process included a public meeting of the FDA’s Antimicrobial Drugs Advisory Committee. At its March 16 meeting, outside experts reviewed Pfizer’s application, FDA analyses, safety data, evidence in vaccinated populations and questions surrounding rebound. The committee voted overwhelmingly that the benefit-risk profile supported approval for high-risk adults.

FDA’s extensive integrated review examined efficacy, safety, pharmacology, labeling and the real-world context created by changing variants and widespread immunity. The record reflects an important transition in COVID therapeutics: the agency is no longer evaluating Paxlovid only against the emergency conditions of late 2021, but as a standard prescription medicine expected to remain in use beyond the formal public-health emergency.

Rebound remains real but does not negate the benefit

One of the most visible concerns around Paxlovid has been recurrence of symptoms or a renewed positive test after an initial recovery. The Centers for Disease Control and Prevention issued a Health Alert Network advisory in May 2022 describing COVID-19 rebound, typically two to eight days after recovery. CDC emphasized that rebound can occur after Paxlovid but may also be part of the natural course of infection and that available reports did not justify withholding treatment from eligible high-risk patients.

Research published in the New England Journal of Medicine found viral-load rebound in both Paxlovid and placebo recipients in the EPIC-HR dataset, suggesting that recurrence is not uniquely caused by the drug. The FDA likewise said available data do not show that a longer or repeated course is routinely needed for rebound in patients who otherwise recover.

Drug interactions remain the most important prescribing constraint

Paxlovid combines nirmatrelvir, which blocks a SARS-CoV-2 protease needed for viral replication, with ritonavir, which slows metabolism of nirmatrelvir and keeps effective drug levels in the bloodstream. That same metabolic effect creates clinically important interactions with many commonly used medicines. Prescribers must review a patient’s medication list and kidney and liver status before treatment. Some interacting medicines can be temporarily held or adjusted; others make Paxlovid inappropriate.

The full approval applies to adults. The existing emergency use authorization continues to cover eligible pediatric patients age 12 and older who weigh at least 40 kilograms, preserving access for adolescents at high risk while pediatric evidence continues to develop. Existing EUA-labeled supplies also remain available during the transition.

A pandemic-era medicine enters routine regulation

The significance of the decision is both clinical and regulatory. Paxlovid was first authorized in December 2021, when the United States was preparing for the Omicron wave and urgently needed an effective oral therapy that could be used at home. Full approval indicates that the agency now considers the evidence sufficient under the ordinary statutory standard for safety and effectiveness in the approved adult population.

That does not make COVID-19 treatment simple. Risk varies enormously by age, immune status, vaccination history and underlying disease, and the absolute benefit of treatment is smaller in people with a low baseline risk of hospitalization. But for adults at high risk, the FDA has now moved Paxlovid from emergency status into the permanent therapeutic toolkit — a milestone in the shift from crisis response toward sustained management of SARS-CoV-2.